Figure 6.
The MRI enhancement nanoparticles in vitro and in vivo. (A) The T2-weighted maps of FO and FMO. (B) The transverse relaxation rate (1/T2) of FO and FMO on the basis of Fe plus Mn concentrations. (C) T2 MR images of HeLa cells post-incubation with FO or Pt-FMOs (5 µg/mL) for 3 h at 37 ºC. (D) T2-weighted MR images of mice after injecting with FO (blue columns) and Pt-FMO (red columns) (2 mg/kg). (E) The corresponding signal-to-noise ratio changes (∆SNR) of Figure (D).